The HYSTER study: the effect of intracervically administered terlipressin versus placebo on the number of gaseous emboli and fluid intravasation during hysteroscopic surgery: study protocol for a randomized controlled clinical trial

Lucilla E. Overdijk 1*, Bart M. P. Rademaker 1, Paul J. M. van Kesteren 1, Peter de Haan 1, Robert K. Riezebos 1 and Oscar C. H. Haude 2

Abstract

Background: Transcervical resection of myoma or endometrium is a safe, hysteroscopic, minimally invasive procedure. However, intravasation of distension fluid is a common phenomenon during these procedures. In a previous study we observed venous gas emboli in almost every patient. The severity of hysteroscopic-derived embolization has been shown to be correlated to the amount of intravasation. In addition, paradoxical gas embolism, which is potentially dangerous, was observed in several patients. Studies have shown a reduction of intravasation by using intracervically administered vasopressin during hysteroscopy. We think that its analog, terlipressin, should have the same effect. In our previous research we observed more gaseous emboli as intravasation increased. Whether or not the insertion of intracervically administered terlipressin leads to a lower incidence and severity of gas embolism is unknown. We hypothesize that intracervically administered terlipressin leads to a reduction of intravasation with a lower incidence and severity of gas embolism. Terlipressin may be of benefit during hysteroscopic surgery.

Methods/design: Forty-eight patients (ASA 1 or 2) scheduled for transcervical resection of large, types 1–2 myoma or extensive endometrium resection will be included. In a double-blind fashion patients will be randomized 1:1 according to surgical treatment using either intracervically administered terlipressin or placebo. Transeosophageal echocardiography will be used to observe and record embolic events. A pre- and post-procedure venous blood sample will be taken to calculate intravasation based on hemodilution. Our primary endpoint will be how terlipressin influences the severity of embolic events. Secondary endpoints include the effect of terlipressin on the amount of intravasation and on hemodynamic parameters.

Discussion: If terlipressin does indeed reduce the number of gaseous emboli and intravasation occurring during hysteroscopic surgery, it would be a simple method to minimize potential adverse events. It also allows for prolonged operating time before the threshold of intravasation is reached, thereby reducing the need for a second operation. (Continued on next page)
Surgical hysteroscopy is an established, minimally invasive procedure. Its advantages consist of a short operating time, rapid post-operative recovery and low morbidity. Although risks and complications during hysteroscopy are rare [1–3] serious complications include fluid overload by intravasation of large amounts of distension fluid and the occurrence of air or gaseous emboli which can be potentially life threatening [3–12]. During hysteroscopic surgery large uterine veins are exposed and may, therefore, be an entry point for gas, air and distension fluid. Most of the symptoms that occur during such an event have either been attributed to the direct effects of venous emboli, such as air lock in the right ventricle (RV), or to the resulting cardiovascular collapse [4]. However, we also observed paradoxical embolism with the passage of venous air or gas into the arterial circulation [13]. This may account for some of the described cardiovascular and neurological symptoms associated with large venous emboli. Indeed, one case of temporary blindness has been associated with paradoxical embolism [10].

In a recent study we observed venous embolism in almost all patients (98%) using either monopolar or bipolar diathermia [14]. In addition, in two patients paradoxical embolism was seen, which raised concern because of its potentially deleterious effects on vital organs. A positive correlation was found between the amount of intravasation and the grade of venous gas embolism.

Guidelines indicate that transcervical surgery should be ceased when intravasation exceeds 2000 ml [15]. For this reason some patients will have to undergo a second operation for removal of the remaining uterine tissue.

Vasopressin and terlipressin (triglycyl-lysine vasopressin) are commonly used drugs with different indications. Vasopressin is a naturally occurring hormone and is secreted by the posterior lobe of the pituitary gland. In some European countries vasopressin is not available and, thus, terlipressin, a synthetic long-acting analog of vasopressin, is used. Owing to its pronounced vasoconstrictive effect within the splanchnic circulation, terlipressin is widely used to treat patients suffering from variceal bleeding during the treatment of hepatorenal syndrome and catecholamine-unresponsive septic shock.

In gynecologic surgery, vasopressin has been used since the 1950s. The utilization of intracervically administered vasopressin has been shown to limit the amount of bleeding and intravasation by its primary effect of vasoconstriction and, therefore, may be of use during hysteroscopic surgery [9, 12, 16–20]. In the Netherlands it is common gynecological practice to use terlipressin intracervically to control bleeding during conization. Because previous studies have shown a reduction of intravasation by vasopressin during hysteroscopy we think that its analog, terlipressin, should have the same effect. Terlipressin is an authorized and licensed product used by many clinicians and its efficacy is supported by sufficient published evidence. Whether intracervically administered terlipressin use leads to a decrease in the incidence and severity of gas embolism and the amount of intravasation is unknown and will be the subject of investigation during this phase IV study. In addition, we will study the effects of terlipressin and gaseous emboli on hemodynamic parameters.
assuming that terlipressin does not result in a 45 to 65% reduction of venous emboli.

Study population
Forty-eight patients (ASA classification 1 or 2) scheduled for transcervical resection of large, types 1–2 myomas or extensive TCR-E will be included. All patients are recruited and treated in the OLVG Hospital in Amsterdam.

Exclusion criteria include patients not expected to benefit from diminished intravasation due to terlipressin utilization. These include patients undergoing transcervical operations for small myomas and minor TCR-E procedures. Procedures that are expected to be short lasting (less than 30 min) are excluded.

Patients with a known contraindication for TEE, such as severe esophageal or gastric disease, hepatic cirrhosis or esophageal varices, will be excluded from the study. In addition, patients aged < 18 years or > 70 years, patients with a history of pulmonary embolism or cardiac disease and patients with a language barrier will be excluded.

Eligible patients are informed of the study by gynecologists and anesthesiologists in the outpatient clinic. All patients receive oral and written information about the study. Final inclusion is always done by one of the researching anesthesiologists. If informed consent is obtained randomization will be done on the day of surgery. From that moment on collection of data starts.

Study medication
The patients in our study will be treated with either intracervically administered terlipressin (Glypressine®, Ferring Pharmaceutical) or placebo. Terlipressin treatment will consist of 20 ml diluted terlipressin at a concentration of 0.0425 mg/ml (one vial Glypressine® 8.5 ml containing 0.1 mg/ml terlipressin diluted with 11.5 ml 0.9% saline (NaCl)). The placebo treatment consists of 20 ml 0.9% saline. The maximum dose of terlipressin administered intracervically will be 0.85 mg. The investigational product will be used in the same way as is commonly used in conization: at the start of the procedure patients will receive a maximum of 20 ml investigational product intracervically injected clockwise in the cervix at four points.

Randomization, blinding and treatment allocation
Randomization for intracervically administered terlipressin or placebo will be performed by our hospital pharmacologist, using blocked randomization in blocks of eight patients with a standard randomization scheme, on a 1:1 ratio. The blinded vials (containing 20 ml diluted terlipressin or 20 ml placebo) will be delivered at the day of surgery to the operating team. Echocardiographic images will be evaluated off line by a trained observer, who is also blinded for the treatment group.

Main study endpoints
The main study parameter is the appearance of any embolic event, either venous or paradoxical in origin. To quantify the degree of embolism by TEE a five-grade scale is used:

- Grade 0: the absence of emboli passing through the heart
- Grade I: the presence of a limited number (< 10 per field of view) of small particles in the right atrium (RA), right ventricle (RV) and right ventricular outflow tract (RVOT)
- Grade II: a moderate number of small particles (10–20 per field of view)
- Grade III: many small particles (> 20 per field of view)
- Grade IV: many small and large particles (> 20 per field of view) completely filling the diameter of the RA, RV and RVOT

Secondary study endpoints
The secondary study endpoints collected during the study are:

1. Hemodynamic parameters: blood pressure, cardiac output and systemic vascular resistance
2. Systolic and diastolic cardiac function
3. Signs of cardiac ischemia
4. Amount of intravasation

These endpoints are measured as follows:

1. Hemodynamic parameters will be measured using standard monitoring and with a non-invasive, beat-to-beat hemodynamic monitor (Nexfin HD, BMEE B.V, Amsterdam, Netherlands)
2. Measurements of systolic and diastolic cardiac function will be assessed by TEE before and just after surgery:
   (a) TEE-derived two-dimensional (2D) strain analysis using speckle-tracking (GE healthcare, EchoPAC™) of longitudinal left and right ventricular systolic strain will be made in each of the three mid-esophageal, longitudinal planes: mid-esophageal, four-chamber view (ME 4ch), mid-esophageal, two-chamber view (ME 2ch), and mid-esophageal, long-axis view (ME LAX)
   (b) Using pulsed-wave Doppler the transmitral flow pattern (E/A ratio) will be recorded for the assessment of left ventricular diastolic function
   (c) The diastolic function will be assessed by the ratio of E/e'. The e' is measured by tissue Doppler
imaging in the basal lateral walls of the mid-esophageal, four-chamber view. The mean e' will be used for the analysis.

3. To exclude myocardial ischemia or damage a continuous, five-lead electrocardiogram (ECG) with ST segment analysis, a post-operative, 12-lead ECG and a high-sensitivity troponin analysis are used.

4. Intravasation will be measured by the surgical team by subtracting the amount of fluid introduced via the resectoscope and the amount of fluid collected by fluid suction.

Furthermore, intravasation will be calculated by the difference between pre- and post-procedure hematocrit (Ht) and hemoglobin (Hb) concentration according to the formula reported by Drobin et al. [21] and Johansson et al. [22]:

\[(a) \text{ (Baseline Hb/Hb after procedure − 1) x plasma volume/1 − baseline Ht}
\]
\[(b) \text{ (ECFV x postop[Cl] − ECFV x preop[Cl])/(154 − postop[Cl])},
\]

where ECFV = extracellular fluid volume, postop = postoperative, preop = preoperative, Cl = plasma chloride concentration.

Study procedures

1. A 5-mHz multiplane TEE probe (Vivid-i GE Vingmed Ultrasound AS, Horten, Norway) will be inserted under general anesthesia after tracheal intubation into the esophagus to obtain a four-chamber view. TEE images will be recorded at set times and all recordings will consist of three cardiac cycles. For baseline measurements the first TEE recording will be made after the insertion of the probe, before installation of terlipressin/placebo and before the start of the surgery. To obtain global strain as an overall measure of ventricular systolic function the three mid-esophageal, longitudinal planes will be viewed: ME 4ch, ME 2Ch, ME LAX.

2. Before installation of terlipressin/placebo a venous blood sample is taken.

3. The blinded study medication is injected intracervically.

4. Two minutes after intracervical injection of the study medication Nexfin-derived hemodynamic variables will be re-recorded.

5. During transcervical surgery TEE images will be made throughout the whole procedure. Images are made when emboli appear on a regular basis with a minimum of 10 loops during the whole procedure.

The total duration of embolic events will also be recorded.

6. The amount of intravasation will be recorded at the end of hysteroscopic surgery.

7. After surgery final TEE recordings will be made. To obtain global strain measures after surgery as an overall measure of ventricular systolic function, the three mid-esophageal, longitudinal planes will be viewed again.

8. After surgery final hemodynamic recordings will be made using the Nexfin HD.

9. After the procedure and final measurements the second venous blood sample is taken.

10. In the recovery room a 12-lead ECG is performed.

11. Three hours after surgery a third blood sample will be taken for high-sensitivity troponin analysis.

The SPIRIT figure HYSTER (Additional file 1) shows in detail the schedule of enrollment, interventions and assessments. For flow diagram HYSTER study see (Fig. 1).

Statistical analysis

- **Descriptive statistics**: data are presented in tables and graphs as totals, means, medians, percentiles and percentages when indicated.

- **Multivariate analysis**: continuous variables (demographic data, intravasation, etc.) will be analyzed using the unpaired T test or the Mann-Whitney U test. Non-parametric data will be analyzed using the chi-square test. Global hemodynamic data (heart rate, cardiac output, etc.) will be analyzed using multivariate analysis of variance (MANOVA) for repeated measures. Post hoc analysis will be done using Dunnett’s post hoc test. Non-parametric data, i.e., grading of the embolic events, will be analyzed using the Wilcoxon signed-rank test. A p value ≤ 0.05 will be considered statistically significant. All statistical analysis will be performed using SPPS (version 22.0.0.1).

- **Univariate analysis**: not applicable.

Data management

Paper, patient records are stored in a designated locker, only accessible to authorized researchers. Electronic patient data are either stored in the hospital electronic health record system or on a password-secured local Sharepoint (Microsoft) server, also only accessible to authorized researchers. Individual files containing patient data are password protected separately. Researchers with access to patient data are BROK-certified. BROK (Basic course on Regulations and Organization for clinical investigators) is a legally required certificate for academic researchers issued by the Dutch Federation for University Hospitals.
Every included patient is allocated a personal study number. If an unexpected finding is discovered requiring further examination (for example, during offline analysis of echocardiography) blinded data can be traced back to individual patients.

Harms
Adverse events, serious adverse events and suspected unexpected serious adverse reactions (AEs, SAEs and SUSARs, respectively) related to the hysteroscopic procedure will be treated according to generally accepted guidelines. Firstly, if needed, the hysteroscopic procedure is stopped. AEs and SAEs related to the installation of the TEE probe (esophageal lacerations, bleeding, etc.) will be treated following consultation with a gastroenterologist and a surgeon. In case of serious cardiac adverse events patients will be treated following consultation with a cardiologist. Owing to its pronounced vasoconstrictive effect within the circulation, the use of terlipressin may result in hypertension with or without reflex bradycardia. This will be treated, if necessary, with the appropriate drugs commonly used in general anesthetic practice Preventive measures in this respect are a proper injection technique (aspiration before injection in order to prevent intravascular injection) and extensive monitoring of heart rate and blood pressure. A 24-h Emergency Code Break and Drug Information can be provided by the hospital pharmacist.

SAEs and SUSARs are always reported to the involved Research Ethics Committee. All AEs, SAEs and SUSARs will be followed up until they have abated, or until a stable situation has been reached. Depending on the event, follow-up may require additional tests, medical procedures, and/or referral to the general physician or a medical specialist. Interim analysis will be done after 25 patients have been included.

As legally required a liability insurance covers potential physical harm inflicted to patients through study procedures.

Discussion
This protocol describes a double-blind randomized trial to compare the effect of intracervically administered terlipressin with placebo in regard to the degree of gaseous embolism and intravasation during hysteroscopic surgery. If terlipressin reduces gaseous embolism and intravasation it would be a potentially simple intervention to make hysteroscopic surgery an even safer procedure. As previously stated, minimizing gaseous emboli and intravasation might reduce the need for a second operation. This study does not only investigate the possible benefits of intracervically administered terlipressin, we also study the effects of terlipressin itself on hemodynamic parameters and specific cardiac parameters using TEE. The results of pre- and post-procedure venous blood gas samples enable the future analysis of acid-base and electrolyte disturbances relating to intravasation during hysteroscopic surgery.

Trial status
At the time of writing this manuscript, 45 patients have been included and treated according to the protocol. The first patient was included April 2014; recruitment is expected to be completed around December 2017.

Additional file

**Additional file 1:** SPIRIT Checklist HYSTER. SPIRIT Checklist HYSTER shows the recommended items to address in a clinical trial protocol with corresponding page numbers. (DOC 122 kb)
Abbreviations
AE: Adverse event; ASA: American Society of Anesthesiologists; Hb: Hemoglobin; Ht: Hematocrit; ME 2ch: Mid-esophageal, two-chamber view; ME 4ch: Mid-esophageal, four-chamber view; ME LAX: Mid-esophageal, long-axis view; NaCl: Sodium chloride solution or saline; RA: Right atrium; RV: Right ventricle; RVOT: Right ventricular outflow tract; SAE: Serious adverse event; SUSAR: Suspected unexpected serious adverse reaction; TCR-E: Transcervical resection of endometrium; TCR-M: Transcervical resection of myomas; TEE: Transesophageal echocardiography

Acknowledgements
We would like to thank B Thiel for his ongoing contributions and support in the study logistics. Additional file 1 shows the SPIRIT Checklist with the recommended items to address in a clinical trial protocol with corresponding page numbers.

Funding
This study is funded by a grant from the OLVG’s Teaching Hospital Foundation. No funding comes from a third party or company. The funding party has no influence on the study protocol neither in any form, nor on the data analysis and any publications following from these data. Contact information: OLVG, Teaching Hospital, Dr. JA van der Zee, PO Box 95500, 1090HM Amsterdam, Netherlands.

Availability of data and materials
The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request after analysis and writing the main article. When data are shared with other parties, they will be made completely anonymous.

Authors’ contributions
LE conceived of the study, wrote the protocol, counseled and included patients, corrected this manuscript and is the corresponding author. BMP helped set up the database. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Medical Research Ethics Committees United has approved the study protocol on 16 March 2015. Changes in the study protocol are reported to the Ethics Committee.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1OLVG Hospital, Oosterparkstraat 9, 1091 AC Amsterdam, Netherlands.
2University of Amsterdam/AMC Hospital, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands.

Received: 8 June 2017 Accepted: 2 January 2018
Published online: 14 February 2018

References
1. Di Spiezio SA, Taylor A, Tsirkas P, et al. Hysteroscopy: a technique for all? Analysis of 5,000 outpatient hysteroscopies. Fertil Steril. 2008;89:438–43.
2. Jansen FW, Vredevoogd CB, van Uden K, et al. Complications of hysterectomy: a prospective, multicenter study. Obstet Gynecol. 2000;96:266–70.
3. Sheiky D, Rojansky N, Revel A, et al. Complications of hysteroscopic surgery: beyond the learning curve. J Minim Invasive Gynecol. 2007;14:218–22.
4. Hieber C, Ibra G, Nachbar S, et al. Near-fatal paradoxical gas embolism during gynecological laparoscopy. Acta Obstet Gynecol Scand. 2000;79:898–9.
5. Nishiyama T, Hanoaka K. Gas embolism during hysteroscopy. Can J Anaesth. 1999;46:379–81.
6. Rademaker BM, Groenenman FA, van der Wouw PA, Bakkum EA. Paradoxical gas embolism by transpulmonary passage of venous emboli during hysteroscopic surgery: a case report and discussion. Br J Anaesth. 2008;101:230–3.
7. Vo VI, Le Bervet JY, Nguyen NQ, Ikiapi C. Fatal gas embolism during hysteroscopy with physiological saline. Presse Med. 1991;20:2107–8.
8. Vo VI, Nguyen NQ, Le Bervet JY. A fatal gas embolism during a hysteroscopy-curettage. Cah Anesthesiol. 1992;40:617–8.
9. Cooper JM, Brady RM. Intraoperative and early postoperative complications of operative hysteroscopy. Obstet Gynecol Clin North Am. 2000;27:347–66.
10. Ghimouz A, Loisel B, Kheyar M, et al. Carbon dioxide embolism during hysteroscopy followed by transient blindness. Ann Fr Anesth Reanim. 1996;15:192–5.
11. Imasogie N, Crago R, Leyland NA, Chung F. Probable gas embolism during operative hysteroscopy caused by products of combustion. Can J Anaesth. 2002;49:1044–7.
12. Kongnyuy EJ, Wyssong CS. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database Syst Rev. 2011;11:CD003355.
13. Rademaker BM, van Kesteren PJ, de Haan P, et al. How safe is the intravasation limit in hysteroscopic surgery? J Minim Invasive Gynecol. 2011;18:355–61.
14. Dyrbye BA, Overdijk LE, van Kesteren PJ, de Haan P, Riezebos RK Bakkum EA, Rademaker BM. Gas embolism during hysteroscopic surgery using bipolar or monopolar diathermia: a randomized controlled trial. Am J Obstet Gynecol. 2012;207:271.e1–6.
15. Ananthanarayan C, Paek W, Rolbin SH, Dhanidina K. Hysteroscopy and anaesthesia. Can J Anaesth. 1996;43:56–64.
16. Conson SL, Brooks PG, Serden SP, et al. Effects of vasopressin administration during hysteroscopic surgery. J Reprod Med. 1994;39:419–23.
17. Phillips DR, Nathanson HG, Milim SJ, et al. The effect of dilute vasopressin solution on blood loss during operative hysteroscopy: a randomized controlled trial. Obstet Gynecol. 1996;88:761–6.
18. Phillips DR, Nathanson H, Milim SJ, Haselkorn JS. The effect of dilute vasopressin solution on blood loss during operative hysteroscopy. J Am Assoc Gynecol Laparosc. 1996;3:supplB.
19. Goldenberg M, Zolli M, Bider D, et al. The effect of intracervical vasopressin on the systemic absorption of glycerine during hysteroscopic endometrial ablation. Obstet Gynecol. 1998;92:1025–9.
20. Chudnoff S, Glazer S, Levie M. Review of vasopressin use in gynecologic surgery. J Minim Invasive Gynecol. 2012;19:422–33.
21. Drobín D, Hahn RG. Volume kinetics of Ringer’s solution in hypovolemic volunteers. Anesthesiology. 1999;90:81–91.
22. Johansson J, Lindahl M, Gyllenhaertz E, Hahn RG. Symptomatic absorption of isotonic saline during transcervical endometrial resection. Acta Anaesthesiologica Scandinavica, 61(1), 121-124. https://doi.org/10.1111/aas.12834.